173 related articles for article (PubMed ID: 38562464)
1. The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future.
Roffel AF; van Hoogdalem EJ
Front Pharmacol; 2024; 15():1369079. PubMed ID: 38562464
[TBL] [Abstract][Full Text] [Related]
2. Dose-linearity of the pharmacokinetics of an intravenous [
van Groen BD; Vaes WH; Park BK; Krekels EHJ; van Duijn E; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Knibbe CAJ; Tibboel D; de Wildt SN; Turner MA
Br J Clin Pharmacol; 2019 Oct; 85(10):2332-2340. PubMed ID: 31269280
[TBL] [Abstract][Full Text] [Related]
3. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
4. Microdosing and drug development: past, present and future.
Lappin G; Noveck R; Burt T
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
[TBL] [Abstract][Full Text] [Related]
5. A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens.
van der Heijden L; van Nuland M; Beijnen J; Huitema A; Dorlo T
Clin Transl Sci; 2023 Feb; 16(2):258-268. PubMed ID: 36419385
[TBL] [Abstract][Full Text] [Related]
6. Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.
Garner CR; Park KB; French NS; Earnshaw C; Schipani A; Selby AM; Byrne L; Siner S; Crawley FP; Vaes WH; van Duijn E; deLigt R; Varendi H; Lass J; Grynkiewicz G; Maruszak W; Turner MA
Br J Clin Pharmacol; 2015 Jul; 80(1):157-67. PubMed ID: 25619398
[TBL] [Abstract][Full Text] [Related]
7. Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin.
Oesterreicher Z; Eberl S; Wulkersdorfer B; Matzneller P; Eder C; van Duijn E; Vaes WHJ; Reiter B; Stimpfl T; Jäger W; Nussbaumer-Proell A; Marhofer D; Marhofer P; Langer O; Zeitlinger M
Clin Pharmacokinet; 2022 May; 61(5):697-707. PubMed ID: 34997559
[TBL] [Abstract][Full Text] [Related]
8. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
Wagner CC; Langer O
Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
[TBL] [Abstract][Full Text] [Related]
9. [Impact of microdose clinical trials in the preclinical stage].
Kim S
Yakugaku Zasshi; 2014; 134(4):459-63. PubMed ID: 24694804
[TBL] [Abstract][Full Text] [Related]
10. Microdosing: current and the future.
Lappin G
Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
[TBL] [Abstract][Full Text] [Related]
11. The utility of microdosing over the past 5 years.
Lappin G; Garner RC
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
[TBL] [Abstract][Full Text] [Related]
12. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.
Burt T; John CS; Ruckle JL; Vuong LT
Expert Opin Drug Deliv; 2017 May; 14(5):657-672. PubMed ID: 27564533
[TBL] [Abstract][Full Text] [Related]
13. A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.
Wagner CC; Simpson M; Zeitlinger M; Bauer M; Karch R; Abrahim A; Feurstein T; Schütz M; Kletter K; Müller M; Lappin G; Langer O
Clin Pharmacokinet; 2011 Feb; 50(2):111-20. PubMed ID: 21142292
[TBL] [Abstract][Full Text] [Related]
14. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.
Bosgra S; Vlaming ML; Vaes WH
Clin Pharmacokinet; 2016 Jan; 55(1):1-15. PubMed ID: 26242381
[TBL] [Abstract][Full Text] [Related]
15. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
Van Nuland M; Rosing H; Thijssen B; Burgers JA; Huitema ADR; Marchetti S; Schellens JHM; Beijnen JH
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):929-937. PubMed ID: 31970932
[TBL] [Abstract][Full Text] [Related]
16. Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose.
Roosendaal J; Groenland SL; Rosing H; Lucas L; Venekamp N; Nuijen B; Huitema ADR; Beijnen JH; Steeghs N
Eur J Clin Pharmacol; 2020 Aug; 76(8):1075-1082. PubMed ID: 32430518
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Microdose Pharmacokinetics.
van Nuland M; Rosing H; Huitema ADR; Beijnen JH
Clin Pharmacokinet; 2019 Oct; 58(10):1221-1236. PubMed ID: 31030372
[TBL] [Abstract][Full Text] [Related]
19. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
Gu H; Wang J; Aubry AF; Jiang H; Zeng J; Easter J; Wang JS; Dockens R; Bifano M; Burrell R; Arnold ME
Anal Chem; 2012 Jun; 84(11):4844-50. PubMed ID: 22540405
[TBL] [Abstract][Full Text] [Related]
20. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
